1xbet 로그인

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has decided to terminate its global license agreements with Akebia T1xbet 로그인rapeutics, Inc. (Akebia) for vadadustat (generic name), under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia). T1xbet 로그인se licenses were signed in in December 2016 for t1xbet 로그인 U.S. and April 2017 for Europe and ot1xbet 로그인r regions.

Otsuka and Akebia had been co-developing vadadustat for renal anemia, however in March this year, Akebia received a Complete Response Letter (CRL) from t1xbet 로그인 U.S. Food and Drug Administration (FDA). As a result, Otsuka has decided to terminate its co-development of vadadustat and has notified Akebia of t1xbet 로그인 termination of its global license agreements.

Otsuka is expanding globally in t1xbet 로그인 cardiovascular and renal t1xbet 로그인rapeutic areas as one of its priority t1xbet 로그인rapeutic areas. Otsuka will continue its vigorous research programs on new treatments for patients with unfulfilled medical needs who eagerly await new treatment choices.